AZ and Daiichi Sankyo needed compelling data for Enhertu because the drug has been linked to an uncommon but potentially dangerous side effect – interstitial lung disease (ILD) – which may be ...

Enhertu is a combination of a chemotherapy drug ... allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug ...

which can have serious side effects. Enhertu is already approved as a third-line therapy for HER2-positive metastatic breast cancer and a second-line therapy for HER2-positive metastatic gastric ...

Enhertu was also approved for HER2-positive ... Participants treated with Datroway also saw fewer severe side effects: the rate of severe adverse events was about 21% in the Datroway group and ...

Enhertu significantly improves overall survival in HER2-positive metastatic gastric cancer compared to ramucirumab and paclitaxel. DESTINY-Gastric04 is the first phase 3 trial showing Enhertu's ...

By then, AstraZeneca and cancer drug partner Daiichi Sankyo had already validated the blockbuster potential of HER2-directed ADCs with Enhertu. But Eisai identified BB-1701 as a potential best-in ...

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...